Fenbendazole, Ivermectin & Mebendazole for Lung Cancer: Critical Evidence Review of 62 Publicly Reported Cases (2026)

Abstract

Background:
Lung cancer, particularly advanced or metastatic non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), remains a leading cause of cancer mortality worldwide. Conventional therapies such as targeted agents, immunotherapy, and chemotherapy offer survival benefits but often yield limited results in treatment-resistant or late-stage disease. Repurposing widely available antiparasitic drugs — fenbendazole, ivermectin, and mebendazole — has garnered attention in integrative oncology communities due to reported anticancer effects in preclinical studies and emerging anecdotal clinical observations.

Objective:
To summarize a compilation of real-world case reports describing the use of fenbendazole, ivermectin, and mebendazole in lung cancer patients, highlighting reported clinical outcomes and therapeutic contexts.

Methods:
This review synthesizes case narratives and outcome descriptions publicly shared through online platforms, including clinicians’ social media posts and patient testimonials. Cases involving lung cancer patients treated with fenbendazole, ivermectin, and/or mebendazole — alone or alongside standard oncology therapies — were examined for disease stage, treatment combinations, and reported tumor responses. Mechanistic rationale from preclinical research was integrated where relevant.

Results:
The compilation includes approximately 60 individual case reports involving patients with Stage III or IV lung cancer (predominantly NSCLC, with some SCLC cases). Many reports describe substantial tumor shrinkage, resolution of metastatic lesions, stabilization of disease, and improvements in clinical symptoms following regimens that combined fenbendazole, ivermectin, and occasionally mebendazole with or without conventional therapies (e.g., targeted therapy like osimertinib, chemotherapy, or radiation). Examples include significant reduction in primary tumor volume and nodal metastases, complete radiographic clearance of brain metastases in certain cases, and prolonged periods of stability in others. While some patients were also receiving approved oncology treatments, several narratives attribute observed improvements in part to the antiparasitic protocol.

Conclusions:
Anecdotal case reports suggest potential anticancer activity associated with fenbendazole, ivermectin, and mebendazole regimens in patients with lung cancer. These observations coincide with preclinical evidence indicating possible inhibition of cancer cell growth and induction of apoptosis. However, the uncontrolled nature of these reports, frequent concomitant use of standard therapies, and lack of systematic outcome verification limit the strength of conclusions. Rigorous clinical trials and controlled studies are necessary to evaluate the safety, dosing, and true efficacy of these repurposed antiparasitic agents in lung cancer treatment before broad clinical recommendations can be made.

Introduction

Lung cancer remains one of the most challenging and deadly malignancies worldwide, with limited effective treatment options for advanced stages despite advances in targeted therapies and immunotherapies. Patients with metastatic or treatment-resistant disease often face poor prognoses and unmet clinical needs, prompting exploration of novel and adjunctive therapeutic approaches.

For patients with actionable mutations identified through molecular profiling, targeted therapies are the preferred treatment approach. In particular, for "PD-L1 High Non-Small Cell Lung Cancer", single-agent immunotherapy may be more effective and better tolerated than chemotherapy in selected patients.

The preference for targeted treatments reflects their demonstrated efficacy in improving outcomes in these molecularly defined subgroups, underscoring the importance of comprehensive genomic profiling in guiding personalized therapy decisions. However, targeted agents are only applicable to small patient subsets.

Repurposing existing drugs with known safety profiles represents a promising strategy to expand the therapeutic arsenal against lung cancer. Fenbendazole, ivermectin, and mebendazole—widely used antiparasitic agents—have recently garnered attention for their potential anticancer properties demonstrated in preclinical studies and emerging clinical observations. These drugs exhibit multiple mechanisms of action, including inhibition of cancer cell proliferation, induction of apoptosis, disruption of microtubule dynamics, and enhancement of anticancer immune responses.

The potential applications of Ivermectin and Fenbendazole in cancer treatment have sparked significant interest online, with growing communities exploring these compounds for therapeutic use. While both have roots in anti-parasitic medicine, emerging research and anecdotal evidence suggest they may offer benefits in combating lung cancers.

In 2025 (Malak et al) - 2025 Paper from Middle East identifies how Ivermectin kills Lung Cancer cells. Authors concluded that in this mouse model (which keeps the immune system intact, unlike some other models), Ivermectin acted as a powerful anti-cancer agent. Ivermectin shrank tumors, reduced inflammation, slowed growth, triggered cancer cell death, and shut down a critical survival/growth pathway (EGFR/PI3K/AKT/mTOR/VEGF), while also promoting apoptosis. The authors concluded that Ivermectin shows promise as a repurposed drug for NSCLC Lung Cancer and call for more studies, including human clinical trials.

In 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Ivermectin was tested at 2mg/kg/day which translates to roughly 5uM in vitro concentration. Lung cancer cell line was ranked no. 4 as one of the most sensitive cancer cell lines.

The main goal with this article is to provide as much clear information as possible for someone dealing with lung cancer. This article deals with the basis and practical approach to using Fenbendazole and Ivermectin for lung cancer.

This article compiles the most recent and compelling case reports and peer-reviewed studies involving fenbendazole, ivermectin, and mebendazole in lung cancer treatment. By examining these real-world therapeutic successes and the underlying scientific rationale, we aim to provide an evidence-informed overview of how these repurposed agents may contribute to improved outcomes for patients battling lung cancer.

Editorial clarification. The 62 cases below should not be interpreted as a prospective clinical cohort, registry, formal case series, or demonstration of treatment efficacy. They are a structured archive of publicly reported lung-cancer narratives involving fenbendazole, ivermectin, mebendazole, or combinations containing one or more of these agents. Most reports originate from testimonials, social-media posts, clinician commentary, patient/family accounts, or integrative-clinic case descriptions. Many patients also received chemotherapy, immunotherapy, radiation, targeted therapy, surgery, or other repurposed medicines. Consequently, the archive cannot establish that any observed response was caused by fenbendazole, ivermectin, or mebendazole.

1. Analytical Objective

The purpose of this reclassification is not to determine whether these drugs work. Instead, it is to determine what kinds of cases are being reported, what treatment patterns recur, what outcomes are described, and how confidently the reported outcomes can be attributed to the antiparasitic agents.

This distinction is important because the original archive contains substantially different evidence types. A patient testimonial with a before-and-after scan is not equivalent to a peer-reviewed case report, and neither is equivalent to a randomized clinical trial.

2. Evidence Taxonomy Used for the Archive

Evidence-level framework

• E0 — Public testimonial: patient/family narrative, social-media post, video, or clinician-posted testimonial without independent clinical adjudication.
• E1 — Structured clinical narrative: a more detailed clinical account containing imaging, biomarkers, treatment chronology, or other medical information but without independent verification.
• E2 — Formal case report/case series: a clinician or clinic describes individual patients in a structured medical case format.
• E3 — Prospective observational evidence: systematic follow-up of a defined patient population.
• E4 — Comparative clinical evidence: controlled comparative study.
• E5 — Randomized controlled evidence: randomized clinical trial.

The present 62-case archive is overwhelmingly E0–E2. It contains no randomized lung-cancer trial establishing efficacy of fenbendazole, ivermectin, or mebendazole.

3. Classification Dimensions

Each case is classified across seven dimensions:

• Clinical phenotype: NSCLC, SCLC, neuroendocrine, mesothelioma, adenocarcinoma, or insufficiently specified.
• Stage: localized/early, Stage III, Stage IV, recurrent/metastatic, or unclear.
• Metastatic pattern: brain, bone, liver, adrenal, lymph-node, pleural/soft tissue, multiple sites, or none reported.
• Repurposed-drug exposure: ivermectin, fenbendazole, mebendazole, or combinations.
• Conventional co-treatment: chemotherapy, immunotherapy, targeted therapy, radiation, surgery, or none reported.
• Reported outcome: complete response/NED, major regression, partial regression, stable disease, biomarker improvement, symptomatic/functional improvement, prolonged survival, or unclear.
• Attribution: how confidently the reported improvement can be associated with the antiparasitic intervention.

4. Full 62-Case Classification Matrix (source)

⇔ Swipe to see the full table

Case	Patient / phenotype	Stage	Metastatic pattern	Repurposed exposure	Standard therapy / co-intervention	Reported outcome	Evidence / attribution
62	72F, lung mass; histology not specified	Unclear	Not reported	Ivermectin + fenbendazole	Clinician-directed protocol; details limited	Complete resolution reported	E0 Public testimonial; attribution uncertain
61	52M, NSCLC	IV	Brain + bone	Ivermectin + fenbendazole + mebendazole + CBD	Chemotherapy + osimertinib	Tumor regression; CEA improvement	E0/E1 Major confounding from active oncology therapy
60	63F, recurrent lung cancer	Recurrent	Not specified	Ivermectin + mebendazole + CBD	Osimertinib	NED reported	E0 Concurrent targeted therapy makes attribution indeterminate
59	64F, NSCLC	IV	Not specified	Ivermectin + fenbendazole + CBD	Chemotherapy	Marked tumor decrease reported	E0 Combination treatment
58	65F, lung cancer	IV	Bone + brain reported	Ivermectin + fenbendazole + CBD + MCP	Prior/unspecified oncology treatment	Prolonged survival reported	E0 Survival attribution highly uncertain
57	67F, SCLC	IV	Pleural	Ivermectin + fenbendazole + melatonin + CBD	Targeted therapy reported	Cancer-free/NED reported	E0 Concomitant treatment
56	63F, pleural mesothelioma + salivary cancer	Advanced	Pleural	Ivermectin + mebendazole + fenbendazole	Not clearly specified	NED reported	E0 Mixed malignancy; attribution uncertain
55	85F, lung cancer	Unclear	Not specified	Ivermectin + fenbendazole	Pembrolizumab + proton therapy	NED/cancer-free reported	E0 Strong confounding by conventional therapy
54	67M, biphasic lung tumor	Recurrent/advanced	Multiple pulmonary nodules	Ivermectin + mebendazole + LDN + doxycycline	Radiation + carboplatin/etoposide	Radiated nodules shrank; untreated nodules grew; QoL preserved	E2 Mixed response; useful internally but not causal evidence
53	86M, squamous lung cancer	IV	Liver	Ivermectin + mebendazole + vitamin D + metformin + propranolol + doxycycline	Radiation	Stable disease reported	E2 Multimodal confounding
52	85M, EGFR-positive adenocarcinoma	IV	Pleural/multifocal	Ivermectin + mebendazole + metformin + propranolol + other integrative agents	Osimertinib	Serial tumor regression/stability	E2 Targeted-therapy confounding
51	80M, EGFR-positive adenocarcinoma	IIIC	No new metastases reported	Ivermectin + mebendazole + multiple repurposed agents	No standard therapy reported	Disease stability	E2 Single uncontrolled clinical narrative
50	60M, ALK-positive adenocarcinoma	IV	Ivermectin + mebendazole + metformin + propranolol + itraconazole	Alectinib	Complete remission reported	E2 Clinic case; alectinib is major confounder
49	65M, lung cancer	IV	Bone	Ivermectin + fenbendazole + mebendazole + CBD	Immunotherapy	Bone lesions decreased	E0 Combination therapy
48	53M, NSCLC	IV	Not specified	Ivermectin + fenbendazole	Not reported	Cancer-free reported; later surgery possible	E0 No independent verification
47	80M, NSCLC	IV	Liver	Ivermectin + fenbendazole + mebendazole	Pembrolizumab	Liver regression; lung stability; functional improvement	E0 Major co-treatment
46	87M, SCLC	IV	Bone	Ivermectin + mebendazole/fenbendazole	Chemotherapy	Tumor burden/bone disease improved	E0 Strong confounding
45	54F, NSCLC	IV	Soft tissue + lymph nodes	Ivermectin + fenbendazole	Osimertinib	~93% reported lung-mass volume reduction; nodal/soft-tissue resolution	E0 Imaging claim; targeted therapy confounding
44	68F, NSCLC	IV	Bone	Ivermectin + fenbendazole	Chemotherapy + KRAS G12C-targeted therapy	>50% regression reported after treatment change	E0 Response occurred after addition/change of conventional targeted therapy
43	67F, large-cell neuroendocrine lung cancer	Unclear	Not reported	Ivermectin + fenbendazole	Not reported	Cancer-free reported	E0 Testimonial
42	59F, pleural mesothelioma	IV	Pleural + abdominal	Ivermectin + fenbendazole + mebendazole	Chemotherapy	Nodular regression reported	E0 Concurrent chemotherapy
41	65M, SCLC	IV	Brain + lymph nodes	Fenbendazole + albendazole	Chemotherapy + radiation + immunotherapy	Major lung regression; brain/nodal resolution reported	E0 Extreme multimodal confounding
40	52M, NSCLC	IV	Bone + brain	Ivermectin + fenbendazole + mebendazole	Not clearly specified	CEA 719→18; tumor regression reported	E0 Biomarker + imaging testimonial
39	81F, early lung cancer	Early/localized	Not reported	Ivermectin + fenbendazole + mebendazole	No chemotherapy/radiation reported	~30% tumor reduction reported	E0 Testimonial; imaging calculation not independently verified
38	83M, multifocal lung cancer	Unclear	Bilateral/multifocal lung disease	Ivermectin + fenbendazole	Not reported	Large radiographic reduction reported	E0 Imaging testimonial
37	69F, lung cancer	IV	Brain	Ivermectin + mebendazole	No oncology therapy reported	Stable/reduced brain and chest disease	E0 One of the lower-confounding narratives, but still uncontrolled
36	51M, NSCLC	IV	Bone	Ivermectin + fenbendazole + mebendazole	Osimertinib	Tumor regression; bone healing reported	E0 Targeted therapy confounding
35	67F, EGFR-mutated NSCLC	IV	Bone + pleural effusion	Ivermectin + fenbendazole	Chemotherapy	Tumor/metabolic and bone improvement; pleural effusion resolved	E0 Major chemotherapy confounding
34	66M, NSCLC	IV	Multiple tumors	Ivermectin + fenbendazole	Immunotherapy	Tumor shrinkage reported over 12 months	E0 Immunotherapy confounding
33	59F, NSCLC	III	Bulky mediastinal/nodal disease	Ivermectin + fenbendazole + mebendazole + other agents	Carboplatin/Taxol + radiation	Marked metabolic and size reduction	E0/E1 Highly confounded multimodal response
32	54F, NSCLC	IV	Lymph nodes + soft tissue/bone regions	Ivermectin + fenbendazole + CBD	Osimertinib + radiation	Major primary and metastatic regression reported	E0 Strong targeted/radiation confounding
31	59F, NSCLC	IV	Brain + bone + nodes	Ivermectin + fenbendazole + mebendazole	Not clearly reported	Lung/nodal and brain lesions resolved; bone disease remained	E0 Imaging testimonial; no control
30	75M, SCLC	IV	Multiple brain metastases	Ivermectin + mebendazole	Not reported	Brain-lesion regression reported	E0 Imaging testimonial
29	55M, multifocal neuroendocrine lung cancer	Unclear/advanced	Multiple pulmonary nodules	Ivermectin + fenbendazole	Not reported	~95% tumor-volume reduction reported	E0 Imaging testimonial
28	62F, SCLC	IV	Brain + liver	Ivermectin + mebendazole + fenbendazole + CBD	Chemotherapy	Major reduction in lung, nodal and liver disease	E0 Chemotherapy confounding
27	61F, NSCLC + large-cell neuroendocrine cancer	Unclear	Not specified	Ivermectin + fenbendazole + Artemisia annua	Not reported	Tumor reduction reported	E0 Patient testimonial
26	59F, NSCLC	III	Lymph nodes	Ivermectin + fenbendazole + mebendazole + itraconazole + doxycycline + DMSO/CBD	Not clearly reported	Large primary/nodal regression reported	E0 Multiple concurrent interventions
25	69F, NSCLC	IV	Bone + pleural disease	Ivermectin + mebendazole + CBD	Not specified	FDG uptake and metastatic burden decreased	E0 Residual active disease remained
24	66F, newly diagnosed lung cancer	Unclear	Not specified	Ivermectin + fenbendazole	Not reported	~95% calculated tumor-volume reduction	E0 Calculation derived from reported dimensions
23	69M, SCLC	III	Not reported	Ivermectin + fenbendazole	Not reported	Near-complete radiographic regression reported	E0 Imaging testimonial
22	64M, NSCLC	IV	History of thyroid cancer	Ivermectin + fenbendazole + CBD	Chemotherapy	Marked primary-tumor reduction reported	E0 Chemotherapy confounding
21	67F, NSCLC	IV	Brain + bone + adrenal + lymph nodes	Ivermectin + fenbendazole + CBD	Not specified	Multisite regression/stability	E0 Imaging testimonial
20	Adult male, metastatic lung disease following head/neck cancer	IV pulmonary recurrence/metastatic	Bilateral lungs	Fenbendazole + ivermectin + vitamins/nutraceuticals	Pembrolizumab + prior radiation/chemotherapy	Stable disease / no recurrence reported	Attribution explicitly uncertain
19	Lung cancer; details limited in current archive	Unclear	Unclear	Repurposed antiparasitic protocol	Unclear	Reported improvement	E0/E1 Insufficient detail for causal classification
18	Adult man, lung cancer	IV	Not specified	Fenbendazole + vitamin D + CBD	Unclear	Tumor regression claimed	E0 Video/social-media report
17	68M, lung cancer	IV	Lymph nodes + bone + liver + spleen + brain	Ivermectin + fenbendazole	Chemotherapy	Multisite shrinkage; large primary-tumor reduction reported	E0 Strong chemotherapy confounding
16	53M, NSCLC	IV	Brain + adrenal + lymph nodes	Ivermectin + mebendazole	Pembrolizumab before/ongoing	Near-complete nodal/adrenal resolution reported	E0/E1 Temporal association only
15	64F, NSCLC	IV	20+ brain metastases	Ivermectin + mebendazole	Not reported	Multiple brain lesions reportedly reduced	E0 Imaging testimonial; uncontrolled
14	45F, NSCLC	IV	Lymph node + liver + adrenal	Ivermectin + fenbendazole	Osimertinib	~75% disease burden reduction reported	E0 Targeted-therapy confounding
13	Adult man, lung cancer	IV	Brain + liver + bone + lymph nodes	Ivermectin + fenbendazole	Oncology treatment reported	Liver/bone metabolic resolution and multisite regression reported	E0 Multimodal confounding
12	Archive entry lacks adequate clinical detail	Unclear	Unclear	Reported in linked source	Unclear	Not reliably classifiable	Unclassifiable Source should be independently retrieved before quantitative analysis
11	Archive entry lacks adequate clinical detail	Unclear	Unclear	Reported in linked source	Unclear	Not reliably classifiable	Unclassifiable Source should be independently retrieved before quantitative analysis
10	40sM, NSCLC	IV	Lymph nodes + pleura + pleural effusion	Ivermectin + fenbendazole	Osimertinib	Primary tumor reduction; pleural effusion resolved	E0 Targeted-therapy confounding
9	40sF, NSCLC	IV	Adrenal + liver + lung lesions	Ivermectin + fenbendazole	Not reported	Stable disease and multisite shrinkage reported	E0 Imaging testimonial
8	Adult woman, Stage IV lung cancer	IV	Lymph nodes + lung	Fenbendazole + curcumin + vitamin E	Targeted gene therapy	Large tumor reduction reported	E0 Targeted therapy confounding
7	Woman in her 70s, lung cancer	IV	Multiple liver metastases	Ivermectin + fenbendazole	Not specified	Primary and hepatic metastasis regression	E0 Imaging testimonial
6	Male, adenocarcinoma	II then recurrent/IV disease	Pleura + multiple pulmonary lesions	Fenbendazole protocol	Chemotherapy + immunotherapy	Pleural disease became unremarkable; other lesions stable	E0 Concurrent chemo/immunotherapy
5	44F, lung adenocarcinoma	IV	Fenbendazole	Chemotherapy + pembrolizumab	Nodules resolved; masses shrank; no new growth reported	E0 Major conventional-treatment confounding
4	SCLC	IV	Joe Tippens-type fenbendazole protocol	Chemotherapy + nivolumab	Brain disease reportedly resolved; systemic disease improved	E0 Strong oncology-treatment confounding
3	Lung carcinoma	IV	Fenbendazole protocol reported	Radiation + intensive chemotherapy	Clinical improvement reported; details incomplete	E0 Insufficient outcome documentation
2	Adult woman, metastatic lung cancer	Metastatic	Fenbendazole protocol	Not specified	Five nodules reportedly reduced to two small nodules	E0 Patient/family testimonial
1	Joe Tippens, SCLC	IV	Fenbendazole + curcumin + CBD + vitamin E	Details of concurrent standard therapy incomplete	Complete-scan response reported	E0 Historical testimonial; not a controlled case

5. Pattern-Based Classification of the 62 Cases

The archive becomes more informative when cases are grouped by recurring clinical patterns rather than presented as a simple list of “success stories.”

Pattern A — Combination therapy dominates.

A large proportion of the reports involve fenbendazole, ivermectin, or mebendazole alongside chemotherapy, immunotherapy, radiation, targeted therapy, surgery, or other repurposed drugs. This means that the dominant real-world pattern is not “antiparasitic drug alone.” It is multimodal treatment.

This is particularly important in cases involving osimertinib, pembrolizumab, alectinib, chemotherapy, or radiation, because each can independently produce objective tumor responses.

Pattern B — NSCLC predominates.

The archive contains many NSCLC narratives, including adenocarcinoma and molecularly defined tumors such as EGFR- and ALK-positive disease. SCLC and neuroendocrine tumors are also represented, while several cases involve mesothelioma.

Pattern C — Advanced disease is disproportionately represented.

Many narratives involve Stage IV disease and metastatic sites such as brain, bone, liver, adrenal glands, lymph nodes, pleura, and soft tissue. This makes the archive clinically interesting as a hypothesis-generating collection of difficult-to-treat cases, but it also introduces substantial selection bias.

Pattern D — Radiographic regression is the dominant reported endpoint.

The most common claims involve reductions in primary tumor size, metastatic lesions, FDG uptake, or tumor-marker levels. Other reported endpoints include stable disease, symptom improvement, improved function, and prolonged survival.

Pattern E — Brain-metastasis narratives form a recurring subgroup.

Several cases specifically report improvement in brain metastases. These observations are hypothesis-generating but should not be interpreted as evidence that any particular drug reliably crosses the blood-brain barrier or treats intracranial metastases. Intracranial response requires standardized MRI-based assessment and appropriate clinical adjudication.

Pattern F — Molecularly targeted therapy is a major confounder.

EGFR- and ALK-positive cases frequently involve osimertinib or alectinib. These therapies have established anticancer activity. Therefore, an observed response after adding an antiparasitic agent cannot automatically be attributed to the repurposed drug.

6. Outcome Classification

The archive should use neutral outcome terminology rather than promotional language. For example, “cancer-free” should be recorded as reported NED unless the underlying imaging, pathology, follow-up duration, and treating-team assessment are independently available.

• CR/NED reported: complete radiographic or clinical response claimed by the source.
• Major regression: substantial tumor reduction reported without enough information to classify a formal complete response.
• Partial regression: measurable reduction in one or more lesions.
• Stable disease: no meaningful progression reported over the stated interval.
• Biomarker response: tumor-marker reduction such as CEA decline.
• Symptomatic/functional response: improved pain, mobility, appetite, performance status, or other patient-reported outcomes.
• Prolonged survival: survival longer than originally predicted, where the prediction itself is documented.
• Unclear: insufficient objective information.

7. Attribution Framework

Each case should also be evaluated according to the degree to which the reported outcome can reasonably be attributed to the repurposed agent.

• A0 — No attribution possible: insufficient information or multiple simultaneous interventions.
• A1 — Temporal association only: improvement occurred after the repurposed drug was introduced, but causality cannot be established.
• A2 — Reduced confounding: the report provides relatively clear chronology and limited concurrent therapy, but remains uncontrolled.
• A3 — Stronger individual-level signal: objective serial imaging, biomarker data, treatment chronology, and limited competing explanations are available.
• A4 — Comparative/controlled evidence: not represented by the current 62-case archive.

The majority of the archive should therefore be considered A0–A1, rather than evidence of causal treatment efficacy.

8. Major Sources of Bias

• Selection bias: dramatic responders are much more likely to be publicly reported than nonresponders.
• Publication/reporting bias: cases describing progression, toxicity, treatment discontinuation, or death may be underrepresented.
• Attribution bias: patients and clinicians may attribute improvement to the newest intervention even when conventional therapy was continued.
• Confounding: targeted therapy, immunotherapy, chemotherapy, radiation, surgery, diet, supplements, and multiple repurposed drugs frequently occur simultaneously.
• Immortal-time and survivorship bias: a patient must survive long enough to generate a testimonial or follow-up scan.
• Measurement bias: some percentage tumor reductions were calculated from reported dimensions rather than independently verified by radiologists.
• Incomplete denominators: the archive does not provide the number of patients who used these interventions without responding.
• Inconsistent follow-up: follow-up duration ranges from weeks to years and is not standardized.
• Diagnostic uncertainty: some entries lack pathology, staging, molecular profiling, or independent confirmation.
• Duplicate-report risk: recurring social-media updates may represent follow-ups of the same patient rather than independent observations.

9. What the 62 Cases Can and Cannot Tell Us

The archive can help identify	The archive cannot establish
Recurring treatment patterns; frequently reported tumor sites; types of patients who are publicly reporting use; hypotheses for prospective research; potential biomarker subgroups; and clinically interesting individual narratives.	Drug efficacy, response rates, survival benefit, optimal dosing, safety, drug-drug interactions, superiority over standard therapy, or causality.
Hypothesis generation for clinical trials and prospective registries.	That fenbendazole, ivermectin, or mebendazole caused a patient's remission.

10. Most Important Clinical Interpretation

The strongest signal emerging from the archive is not that one antiparasitic drug produces consistent lung-cancer remission. Rather, the archive shows a recurring multimodal-treatment phenotype: patients frequently combine repurposed agents with targeted therapy, immunotherapy, chemotherapy, radiation, metabolic interventions, and supplements.

This makes the archive useful as a hypothesis-generating evidence map, but substantially weaker as a causal efficacy dataset.

For example, a patient receiving an EGFR inhibitor who subsequently experiences tumor shrinkage after adding ivermectin and fenbendazole represents an interesting clinical observation. It does not demonstrate that the antiparasitic agents caused the response. The same principle applies to patients receiving chemotherapy, immunotherapy, radiation, or multiple repurposed agents.

11. Proposed Prospective Research Model

The recurring patterns suggest a more rigorous research pathway:

1. Prospectively register consecutive patients rather than selectively collecting responders.
2. Document pathology and complete molecular profiling.
3. Record all standard and complementary therapies with start/stop dates.
4. Use standardized RECIST-based imaging assessment where appropriate.
5. Record objective biomarker trajectories such as CEA only where clinically relevant.
6. Separate targeted-therapy responders from patients without active standard therapy.
7. Predefine progression-free survival and overall survival endpoints.
8. Prospectively capture adverse events and drug interactions.
9. Use independent radiologic review whenever feasible.
10. Ultimately test the most promising combinations in controlled clinical trials.

12. Discussion

The 62 publicly reported lung-cancer narratives constitute a heterogeneous, hypothesis-generating archive rather than a conventional clinical case series. The reports include NSCLC, SCLC, neuroendocrine tumors, adenocarcinoma, and mesothelioma, with a substantial proportion involving advanced or metastatic disease. Reported outcomes include tumor regression, stable disease, metabolic improvement, symptomatic improvement, and claims of complete response or NED.

These antiparasitic agents (ivermectin, fenbendazole and mebendazole), although traditionally used for infectious diseases, exhibit promising anticancer mechanisms—such as inhibition of microtubule polymerization, induction of apoptosis in cancer cells, modulation of tumor microenvironment, and immune stimulation—that align well with the observed tumor responses across multiple lung cancer subtypes, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

The real-world observations presented in this compilation reveal meaningful tumor shrinkage, reduced metastatic burden, and symptomatic improvement in heavily pretreated or advanced-stage lung cancer patients who often have limited conventional treatment options. Remarkably, some patients experienced dramatic lesion resolution, including brain metastases responding to these repurposed agents either alone or in combination with chemotherapy or immunotherapy, suggesting potential chemo- and radiosensitizing properties.

However, it is important to interpret these findings with caution due to the anecdotal nature of much of the current evidence and the absence of large-scale randomized controlled trials (RCTs). Barriers such as limited funding, regulatory challenges, and hesitance within mainstream oncology community have impeded rigorous clinical validation. Additionally, optimal dosing regimens, drug interactions, and long-term safety profiles require further investigation.

Nevertheless, these case series highlight the urgent need for well-designed prospective trials and patient registries to systematically evaluate efficacy and safety, identify predictive biomarkers, and refine patient selection criteria. Integrative oncology protocols combining these repurposed drugs with standard therapies and supportive care may offer a multifaceted approach to improve outcomes for patients with lung cancer, particularly those with aggressive or resistant disease.

Collaboration between conventional oncologists, integrative practitioners, and research researchers will be essential to translate these promising observations into evidence-based clinical guidelines. Meanwhile, patient-centered shared decision-making and careful monitoring should guide the incorporation of fenbendazole, ivermectin, and mebendazole into personalized treatment plans.

In summary, while still preliminary, the accumulating evidence suggests that repurposed antiparasitic drugs warrant serious consideration as adjuncts in lung cancer treatment. Their affordability, wide availability, and observed clinical activity offer hope for expanding therapeutic options in this challenging disease.

Conclusion and Key Takeaway

Keep in mind that these references are based on case reports, which offer preliminary evidence. Critics may dismiss them as pseudoscience or low-quality data or even misinformation. However, these testimonials could represent just the tip of the iceberg—an emerging frontier that science is only beginning to explore.

In a broader context, emerging 2026 evidence on insulin resistance and cancer risk, together with growing evidence linking higher ultra-processed food consumption to poorer health and cancer outcomes, and new research on dietary preservatives, strengthens the case that nutrition should not be dismissed as a mere “lifestyle nicety.” Rather, diet quality and metabolic health should be regarded as foundational components of cancer prevention and supportive care—alongside, not instead of, evidence-based oncologic treatment.

For a more comprehensive understanding, it's worth looking into additional research studies and clinical trials. As always, consult with your healthcare provider(s) before making any treatment decisions, as close monitoring and personalised care are essential.

Sources and References:

1. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients
2. Ivermectin and Fenbendazole or Mebendazole in Cancer: Peer-Reviewed Protocol in Cancer
3. Ivermectin and Cancer: Anti-cancer Mechanisms of Action
4. Fenbendazole and Cancer: Anti-Cancer Mechanisms of Action
5. AI Predicts Ivermectin and Mebendazole Combined with Pembrolizumab, Adagrasib, Nutraceuticals, and Tailored Diet/Lifestyle Improved Overall Survival in Stage 4 Non Small Cell Lung Cancer
6. Drug Repurposing for Cancer Therapy 2025: From AI-Driven Discovery to Practice-Changing Clinical Trials.
7. Fenbendazole and Other Stage 4 Cancer Types: The compilation includes over 250 stage 4 cancer case reports across 17 cancer types. Full details are provided in the following: Stage 4 Cancer Remissions with Fenbendazole, Ivermectin and Mebendazole (December 2025 Edition).
8. Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 466 Case Reports Compilation of various stages (stages 1 to 4) of different cancer types (January 2026 Edition). (One Day MD 2025)
9. Tagrisso (osimertinib) for EGFR mutated NSCLC (YouTube 2022)
10. Lung Cancer Research and Clinical Management in 2026: Precision Oncology, Immunotherapy, and Emerging Signals From Drug Repurposing (Cancer Advisor 2026)
11. This case series is part of the 'Ivermectin, Fenbendazole, and Mebendazole Cancer Case Series' (700+ case reports).
12. Lung Cancer in Non-Smokers Is on the Rise — Experts Explain Why (Fox News July 2025)
13. Case-level source material: OneDayMD, "Ivermectin and Mebendazole for Lung Cancer: A Case Series of 62 Case Reports" (August 2026 update), and the public social media/Substack posts cited therein.

Evidence Hierarchy for Readers

The 62-case archive should be positioned within the broader evidence hierarchy:

1. Randomized controlled trials — strongest evidence for treatment efficacy.
2. Prospective comparative studies — useful for effectiveness and safety.
3. Prospective registries/cohorts — useful for real-world outcomes.
4. Formal case reports/case series — useful for unusual responses and hypothesis generation.
5. Clinician/patient case narratives — useful for signal detection but highly vulnerable to bias.
6. Mechanistic/preclinical studies — useful for biological plausibility but not proof of clinical benefit.

The present archive belongs primarily to level 4 - 5 of this hierarchy. That does not make the observations worthless; it defines what questions they are capable of answering.

Editorial note: This classification is intentionally conservative. “Reported” means that the outcome was described by the source; it does not mean that OneDayMD independently verified the diagnosis, imaging, treatment chronology, or causal attribution. The matrix should therefore not be used to calculate treatment response rates or to recommend self-treatment.

Disclaimers:

• Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
• Please do not consider this guide as personal medical advice, but as a recommendation for use by professional providers. Consult with your doctor and discuss with her/him. Do take note that cancer is a continuous struggle between the immune system and the cancer cells. Cancer treatments are meant to assist the immune system in this battle. Any potential treatment—whether conventional or complementary—must be evaluated on a case-by-case basis, with careful consideration of the benefit-risk ratio to ensure both safety and efficacy.
• The case reports presented reflect the real-life experiences and opinions of other readers or users of the website. The experiences of those readers or users are personal to those particular readers/users and may not necessarily be representative of all readers/users. We do not claim, and you should not assume, that all other readers/users will have the same experiences. Do you own research, consult with relevant medical professionals before attempting to self-treat for any condition.
• Cancer treatment should be part of a multi-modal approach in order to provide the best possible outcome. Diet and lifestyle changes are meant to run alongside conventional treatment. They are complementary, not alternative. 
• Cancer care is a team effort with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dieticians and other allied healthcare professionals.
• While the term 'alternative' might imply opposition to conventional oncology, we prefer 'complementary,' 'integrated,' or 'holistic.' These terms better reflect the role of these strategies as part of a personalized value-added menu of strategies, ensuring the most effective and safe solutions for patients.
• Integrating a repurposed drug doesn't mean rejecting modern medicine — It enhances it and offers a more comprehensive approach to wellness and healing. By combining conventional cancer management with root-cause resolution, this model creates a path to sustained recovery and resilience. 
• For an evidence-graded overview of repurposed cancer drugs, see our full guide.